A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL
Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Josie Montegaard(Dana-Farber Cancer Institute), Mark Choiniere(Dana-Farber Cancer Institute), Karen Francoeur(Dana-Farber Cancer Institute), Jacob D. Soumerai(Harvard University), David C. Fisher(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), Alexandra Savell(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute)
Cited by 9
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752